Erasca (ERAS) Competitors

Erasca (NASDAQ:ERAS) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Does the MarketBeat Community prefer ERAS or KYMR?

Kymera Therapeutics received 29 more outperform votes than Erasca when rated by MarketBeat users. However, 71.43% of users gave Erasca an outperform vote while only 52.94% of users gave Kymera Therapeutics an outperform vote.

Company	Underperform	Outperform
Erasca	Outperform Votes 25 71.43%	Underperform Votes 10 28.57%
Kymera Therapeutics	Outperform Votes 54 52.94%	Underperform Votes 48 47.06%

Do institutionals & insiders hold more shares of ERAS or KYMR?

67.8% of Erasca shares are owned by institutional investors. 21.5% of Erasca shares are owned by insiders. Comparatively, 15.8% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has preferable valuation and earnings, ERAS or KYMR?

Erasca has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$125.04M	-$0.83	-2.23
Kymera Therapeutics	$78.59M	33.46	-$146.96M	-$2.34	-17.35

Is ERAS or KYMR more profitable?

Erasca has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -191.26%. Kymera Therapeutics' return on equity of -24.96% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-42.26%	-34.97%
Kymera Therapeutics	-191.26%	-24.96%	-20.27%

Which has more volatility and risk, ERAS or KYMR?

Erasca has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500.

Do analysts rate ERAS or KYMR?

Erasca currently has a consensus target price of $5.70, suggesting a potential upside of 208.11%. Kymera Therapeutics has a consensus target price of $55.38, suggesting a potential upside of 36.36%. Given Erasca's stronger consensus rating and higher probable upside, equities analysts clearly believe Erasca is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Kymera Therapeutics	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Does the media prefer ERAS or KYMR?

In the previous week, Kymera Therapeutics had 6 more articles in the media than Erasca. MarketBeat recorded 9 mentions for Kymera Therapeutics and 3 mentions for Erasca. Erasca's average media sentiment score of 0.72 beat Kymera Therapeutics' score of 0.57 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Erasca beats Kymera Therapeutics on 10 of the 18 factors compared between the two stocks.